Drug Database
ME

meningococcal B vaccine (rLP 2086 / PF05212366 / MnB rLP2086)

✓ Approved

Pfizer, Inc. · · Recombinant Proteins

What is meningococcal B vaccine?

meningococcal B vaccine is a recombinant proteins developed by Pfizer, Inc.. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Brand NamesrLP 2086, PF05212366, MnB rLP2086
CompanyPfizer, Inc.
Drug ClassRecombinant Proteins, Vaccine
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, Pfizer, Inc.

Mechanism of Action

Molecular Targets

meningococcal B vaccine acts on 1 molecular target:

()
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

meningococcal B vaccine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsMeningococcal bacteraemia✓ Approved

Related Research Articles

PubMedAAPS PharmSciTech2026-09-19

Comprehensive Stability Assessment of Squalene in a Nanoemulsion Adjuvant and the SpiN-Tec Vaccine: HPLC Quantification, Stress Testing, and Stability Studies.

Gomes Isabela Pereira IP, Rivelli Graziella Gomes GG, Bagno Flávia Fonseca FF, Hojo-Souza Natália Satchiko NS et al.

Squalene-based nanoemulsions are widely used as adjuvants in vaccine formulations, but their stability can be affected by environmental factors such as pH, oxidative stress, temperature, and light. We have produced a squalene nanoemulsion (CTVad1) to support the clinical development of new vaccines. This study aimed to develop and validate an HPLC method for squalene quantification in SpiN-Tec, a recombinant protein vaccine against COVID-19. We also aimed to evaluate the stability of the CTVad1 adjuvant and SpiN-Tec under controlled storage conditions. A reversed-phase HPLC method was developed and validated, and comprehensive forced degradation studies were performed on the raw material and SpiN-Tec under acidic, basic, oxidative, thermal, and photolytic conditions to demonstrate the stability-indicating capability of the method. Physicochemical, morphological, and biological characteristics were assessed, and stability studies of both the vaccine and the CTVad1 adjuvant were performed under accelerated and long-term conditions. The HPLC method was selective, precise, accurate, linear, and robust. Squalene raw material degraded under all tested conditions, whereas formulation in nano-sized globules improved its stability, with degradation observed only under hydrogen peroxide and light exposure. CTVad1 remained stable over time, exhibiting only minor, non-critical changes within the specification limits in both accelerated and long-term stability studies, regardless of the glass packaging used (clear or amber). In addition, the SpiN-Tec vaccine maintained its physicochemical and biological integrity under all tested conditions, with all evaluated parameters remaining within the established specification ranges. Our findings demonstrate that proper formulation, packaging, and storage conditions can preserve squalene stability in nanoemulsion-based vaccines, ensuring the quality, safety, and efficacy of the SpiN-Tec vaccine and its adjuvant throughout shelf life.

PMID 42760453
Read full article →
PubMedOcular immunology and inflammation2026-09-19

Bilateral Maculopathy in an Infant Following Measles, Mumps, Rubella, and Varicella-Zoster (MMRV) Vaccination.

Ben-Avi Ravid R, Amer Radgonde R

To report on the long-term clinical outcome of a healthy infant who presented with posterior uveitis following the administration of the combined measles, mumps, rubella, and varicella (MMRV) vaccine. Descriptive case report. A 13-month-old infant presented with bilateral visual loss two weeks after receiving the MMRV vaccine. Ophthalmic examination revealed bilateral retinitis and retinal vasculitis with exudative retinal detachment. Extensive infectious work-up was conducted including serologic exams and PCR testing of blood, aqueous humor, cerebrospinal fluid and urine. Serological tests for measles yielded positive IgM and IgG titers. PCR testing for measles in the aqueous humor and urine was negative. Neurologic assessment and neuroimaging were unremarkable, excluding central nervous system involvement. Empiric systemic antiviral and corticosteroid therapy was initiated. Gradual resolution of posterior uveitis ensued, culminating in bilateral macular scars. Over a six-year follow-up period, the patient demonstrated stable ocular findings with no evidence of recurrent inflammation or systemic autoimmune disease. Final visual acuity was 6/9 in each eye. This case represents a rare occurrence of non-necrotizing retinitis following MMRV vaccination. To our knowledge, this is the first report describing the sequential OCT characteristics of presumed measles vaccine-associated retinitis. The prolonged follow-up period supports the absence of an alternative etiology and provides valuable insight into the long-term course and visual prognosis of vaccine-associated retinopathy.

PMID 42760840
Read full article →
PubMedAllergologia et immunopathologia2026-09-19

Products of compound probiotics combined with zinc and vitamin B ameliorate the risk of food allergy.

Lu Hanming H, Zhang Liwen L, Ren Mingxing M, Xue Guochang G et al.

Probiotics have emerged as a promising avenue for modulating immune responses implicated in food allergies, with zinc and vitamin B also exhibiting antiallergic properties. However, the clinical efficacy of compound probiotics combined with these nutrients in mitigating food allergy risk remains to be elucidated. In this randomized controlled trial, 796 children aged 0-6 years with food allergies were assigned to either an experimental group receiving compound probiotics, zinc, and vitamin B products alongside hydrolyzed protein formula milk, or a control group receiving only hydrolyzed protein formula milk. Serum IgE levels, specific food allergies, and key immunological factors were assessed at baseline, posttreatment, and post-follow-up time points. The experimental group demonstrated significantly reduced skin-prick test wheal diameters and serum total IgE levels compared with the control group after the 6-month intervention, with sustained efficacy at the 6-month follow-up. Furthermore, the prevalence of specific food allergies, including egg, milk, crab, shrimp, cashew, beef, mango, and shellfish, was significantly lower in the experimental group posttreatment and post-follow-up, highlighting the therapeutic potential of the intervention. Immunological analysis revealed a favorable modulation of Th1/Th2 balance, with increased IFN-γ levels and decreased IL-4 levels in the experimental group. Additionally, serum zinc and vitamin B2 levels were significantly elevated in the experimental group posttreatment and post-follow-up, indicating improved nutritional status. Compound probiotics combined with zinc and vitamin B represent a promising intervention for reducing the risk of food allergies in children, offering a multifaceted approach to immune modulation and nutritional support in this vulnerable population.

PMID 42760882
Read full article →
PubMedbioRxiv : the preprint server for biology2026-09-19

Programmed Clonal Expansion Associated with V(D)J Recombination Drives an ATM-Dependent Vulnerability Underlying Preferential Lymphocyte Depletion and Myeloid Bias Following DNA Damage.

Lee Katherine H KH, Shao Zhengping Z, Wang Yunyue Y, Lee Brian J BJ et al.

Myeloid bias is a hallmark of aging and genotoxic stress, yet the mechanisms underlying the preferential suppression of lymphopoiesis and the resulting predominance of myeloid cells following DNA damage remain incompletely understood. Here, we systematically characterized the acute hematopoietic response to a clinically relevant 2 Gy dose of ionizing radiation in young adult mice. Forty-eight hours after irradiation, overall bone marrow cellularity was reduced by ∼50-60%, with hematopoietic stem and progenitor cells (HSPCs) and myeloid populations declining proportionally. Strikingly, immature and naïve B cells in the bone marrow and developing T cells in the thymus exhibited profound hypersensitivity, declining by ∼90%, thereby recapitulating the preferential vulnerability of lymphocytes to DNA damage. Single-cell RNA sequencing mapped this vulnerability to cells undergoing programmed clonal expansion associated with V(D)J recombination. Specifically, B and T lymphocytes immediately following productive V(D)J recombination at the immunoglobulin heavy-chain (IgH) and T-cell receptor β (TCRβ) loci were the most radiosensitive, resulting in the marked depletion of the immediately downstream small pre-B and CD4⁺CD8⁺ double-positive (DP) thymocyte populations. Mechanistically, this stage-specific radiosensitivity was mediated by ATM-dependent DNA damage responses, as Atm deficiency selectively rescued the hypersensitivity of clonally expanding lymphoid progenitors while leaving the global reduction of HSPCs and myeloid cells largely unchanged. Rapidly proliferating S3 erythroblasts also exhibited a similar ATM-dependent hypersensitivity, suggesting that programmed proliferative bursts may represent a general determinant of radiation sensitivity. Together, these findings identify programmed clonal expansion associated with V(D)J recombination as an intrinsic developmental vulnerability that underlies the preferential suppression of lymphopoiesis following DNA damage and provides a mechanistic explanation for the emergence of myeloid bias. 2 Gy irradiation preferentially depletes developing mouse B and T cells beyond global hematopoietic lossProgrammed clonal expansion drives ATM-dependent DNA damage sensitivity in developing lymphocytes.

PMID 42760984
Read full article →
PubMedMedicine2026-09-19

Primary breast diffuse large B-cell lymphoma mimicking breast carcinoma: A case report and literature review.

Li Longquan L, Yao Hongxi H, Liu Siyu S, Yin Jieting J et al.

Primary breast diffuse large B-cell lymphoma (PB-DLBCL) is a rare extranodal manifestation of non-Hodgkin lymphoma (NHL) that can closely resemble breast carcinoma clinically and radiologically. This overlap may delay accurate diagnosis and appropriate treatment. We report a case of PB-DLBCL in a postmenopausal woman whose initial multimodal imaging findings were suspicious for breast carcinoma, but whose final diagnosis was established by core needle biopsy with immunohistochemical and molecular evaluation. A 59-year-old postmenopausal woman presented with a painless, palpable mass in the right breast that had been present for approximately 3 weeks. Breast ultrasonography, mammography, magnetic resonance imaging (MRI), and positron emission tomography/computed tomography (PET/CT) demonstrated a suspicious right breast mass with ipsilateral axillary lymphadenopathy, initially raising concern for breast carcinoma. Ultrasound-guided core needle biopsy showed diffuse infiltration by atypical lymphoid cells. Immunohistochemistry confirmed a B-cell phenotype, and fluorescence in situ hybridization (FISH) showed no MYC, BCL2, or BCL6 rearrangements. Bone marrow biopsy showed no evidence of marrow involvement. The final diagnosis was PB-DLBCL, non-germinal center B-cell-like (non-GCB) subtype, Ann Arbor stage IIE. The patient received 6 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemoimmunotherapy. No breast-directed surgery, consolidative radiotherapy, or central nervous system prophylaxis was administered. At 6 weeks after completion of R-CHOP therapy, PET/CT showed complete metabolic resolution of the right breast lesion, with only a residual punctate calcified focus measuring approximately 0.4 × 0.4 × 0.3 cm. The Deauville score decreased from 5 at baseline to 1 after treatment, meeting Lugano criteria for complete response. No clinically significant treatment-related adverse events were documented. PB-DLBCL can closely mimic breast carcinoma on multimodal imaging. Suspicious breast imaging findings do not exclude lymphoma. Tissue diagnosis with adequate immunophenotypic and molecular evaluation is essential before definitive treatment planning to avoid misdiagnosis and unnecessary surgery.

PMID 42760664
Read full article →
PubMedNaunyn-Schmiedeberg's archives of pharmacology2026-09-19

TRIM28 facilitates diffuse large B-cell lymphoma progression by inducing glycolytic reprogramming through the E2F1/PKM2 axis.

Xin Liuyan L, Li An A, Xiao Wei W, Yu Jiaqi J et al.

Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous malignancy in which metabolic adaptation contributes to aggressive behavior and treatment resistance. Although TRIM28 has been implicated in several cancers, its role in DLBCL remains unclear. Here, we investigated the function of TRIM28 in DLBCL progression and glycolytic reprogramming. TRIM28 expression was elevated in the TCGA DLBC cohort and in DLBCL cell lines compared with the normal B-cell line GM12878, and it was positively correlated with PKM2 expression in GEPIA. Gain- and loss-of-function assays showed that TRIM28 promoted cell proliferation and migration while suppressing apoptosis. Metabolic analyses further demonstrated that TRIM28 increased extracellular acidification, ATP production, lactate generation, and the expression of glycolysis-related genes, including PFKFB3, HK2, and PKM2. Mechanistically, bioinformatic analysis and dual-luciferase reporter assays identified PKM2 as a transcriptional target of E2F1, and TRIM28 upregulated E2F1 at both mRNA and protein levels, suggesting that TRIM28 acts upstream of the E2F1/PKM2 axis. Importantly, silencing either E2F1 or PKM2 markedly attenuated the effects of TRIM28 on DLBCL cell growth, migration, and glycolytic activity. In a xenograft model, TRIM28 overexpression accelerated tumor growth, whereas E2F1 or PKM2 knockdown significantly reversed these effects. Collectively, TRIM28 facilitates DLBCL progression by inducing glycolytic reprogramming through the E2F1/PKM2 axis, highlighting a potential therapeutic target.

PMID 42760375
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about meningococcal B vaccine